1. Home
  2. LOAN vs CNTX Comparison

LOAN vs CNTX Comparison

Compare LOAN & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$3.89

Market Cap

47.6M

Sector

Real Estate

ML Signal

HOLD

Logo Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

HOLD

Current Price

$0.39

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
CNTX
Founded
1989
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.6M
47.7M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
LOAN
CNTX
Price
$3.89
$0.39
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$6.60
AVG Volume (30 Days)
24.7K
1.6M
Earning Date
04-16-2026
05-08-2026
Dividend Yield
10.06%
N/A
EPS Growth
N/A
17.39
EPS
0.21
N/A
Revenue
$8,666,307.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.89
$0.34
52 Week High
$5.79
$3.62

Technical Indicators

Market Signals
Indicator
LOAN
CNTX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
LOAN
CNTX

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: